The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: a post-hoc analysis of the HARUKA phase 3 study.
Yoshiya TanakaToshiya TakahashiHubert van HoogstratenNaoto KatoHideto KamedaPublished in: Modern rheumatology (2024)
UP and inflammation were reduced in patients with active RA in Japan in both SAR monotherapy and SAR+csDMARDs treatment groups.